Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Guardant Health, Inc. - Common Stock
(NQ:
GH
)
107.96
+0.85 (+0.79%)
Streaming Delayed Price
Updated: 1:43 PM EST, Feb 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Guardant Health, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow
February 17, 2026
Diagnostics company Guardant Health (NASDAQ:GH) will be reporting results this Thursday after market hours. Here’s what to expect.
Via
StockStory
Topics
Artificial Intelligence
Economy
World Trade
3 Unprofitable Stocks Walking a Fine Line
February 15, 2026
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Via
StockStory
Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes
February 13, 2026
In a decisive shift for equity markets, the small-cap heavy Russell 2000 index outperformed its large-cap peers on Friday, February 13, 2026, as investors cheered a cooler-than-expected Consumer Price...
Via
MarketMinute
Topics
Bonds
ETFs
Economy
Guardant Health to Participate in Upcoming Investor Conferences
February 03, 2026
From
Guardant Health, Inc.
Via
Business Wire
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions
February 02, 2026
From
Guardant Health, Inc.
Via
Business Wire
3 Unpopular Stocks We Think Twice About
February 01, 2026
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...
Via
StockStory
Should You Buy Guardant Health Before Feb. 19?
↗
January 30, 2026
This genomics stock appears to be at an inflection point.
Via
The Motley Fool
Topics
Earnings
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
January 29, 2026
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
January 22, 2026
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
January 19, 2026
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group
January 14, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Guardant Health (NASDAQ:GH) and its peers.
Via
StockStory
CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside
January 14, 2026
Via
AB Newswire
Topics
Intellectual Property
GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth
January 13, 2026
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an...
Via
MarketMinute
Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization
January 13, 2026
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that...
Via
MarketMinute
Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability
January 12, 2026
On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025...
Via
MarketMinute
Topics
Artificial Intelligence
Death
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
January 11, 2026
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families
January 08, 2026
From
Guardant Health, Inc.
Via
Business Wire
BTIG's Top Stock Picks for H1 2026: Navigating the New 'Application' Era
January 02, 2026
As the financial markets open for the 2026 calendar year, BTIG has released its highly anticipated "Top Picks" report for the first half of the year, signaling a transition from the speculative fervor...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
1 Growth Stock Set to Flourishand 2 We Avoid
January 01, 2026
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Via
StockStory
The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off
December 30, 2025
As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 29, 2025
From
Guardant Health, Inc.
Via
Business Wire
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line
↗
December 28, 2025
Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface.
Via
The Motley Fool
Topics
Regulatory Compliance
Q3 Earnings Roundup: Cardinal Health (NYSE:CAH) And The Rest Of The Healthcare Providers & Services Segment
December 17, 2025
Looking back on healthcare providers & services stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Cardinal Health (NYSE:CAH) and its peers.
Via
StockStory
Topics
Economy
Q3 Rundown: The Ensign Group (NASDAQ:ENSG) Vs Other Healthcare Providers & Services Stocks
December 15, 2025
Looking back on healthcare providers & services stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including The Ensign Group (NASDAQ:ENSG) and its peers.
Via
StockStory
Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.
December 11, 2025
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy
December 09, 2025
From
Guardant Health, Inc.
Via
Business Wire
3 Volatile Stocks Walking a Fine Line
December 07, 2025
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.
Via
StockStory
Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium
December 05, 2025
From
Guardant Health, Inc.
Via
Business Wire
Why Guardant Health (GH) Stock Is Up Today
December 03, 2025
Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 1.8% in the afternoon session after Morgan Stanley raised its price target on the stock, reflecting heightened optimism about the...
Via
StockStory
Healthcare Providers & Services Stocks Q3 Recap: Benchmarking AMN Healthcare Services (NYSE:AMN)
December 01, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at AMN Healthcare Services (NYSE:AMN) and its peers.
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.